Trial Profile
A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 03 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 17 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Apr 2015 New trial record